In orthotopic breast cancer models, entrectinib plus pacritinib suppressed tumor growth. Entrectinib alone did not significantly suppress BT474-TtzmR xenograft growth, but did suppress growth of BCM-3887 PDX tumors versus vehicle. These responses are specific to the tested models and regimens. [2]
HER2-positive trastuzumab-refractory orthotopic xenografts
Animal study · BT474-TtzmR mammary-fat-pad xenografts in female athymic nude mice [2]
Combination treatment suppressed tumor growth versus vehicle and single agents; neither single agent significantly altered tumor growth or endpoint tumor mass.
Conditions shared by the study groups
- Route
- Oral
- Frequency
- Twice daily, 5 days/week
- Treatment course
- From day 9 to study endpoint (day 35 shown).
- Vehicle
- 100% PEG
- Vehicle
- Model: BT474-TtzmR mammary-fat-pad xenografts in female athymic nude mice
- Reported limits: No lot or salt designation. Vehicle composition beyond 100% PEG not specified in acquired main text.
- Entrectinib
- Model: BT474-TtzmR mammary-fat-pad xenografts in female athymic nude mice
- Reported limits: No lot or salt designation. Vehicle composition beyond 100% PEG not specified in acquired main text.
- Pacritinib
- Model: BT474-TtzmR mammary-fat-pad xenografts in female athymic nude mice
- Reported limits: No lot or salt designation. Vehicle composition beyond 100% PEG not specified in acquired main text.
- Entrectinib + pacritinib
- Model: BT474-TtzmR mammary-fat-pad xenografts in female athymic nude mice
- Reported limits: No lot or salt designation. Vehicle composition beyond 100% PEG not specified in acquired main text.
Methods and source locations
Compound reported in the paper: Entrectinib; Compound label in the paper: Entrectinib alone or with pacritinib
Supplier attribution applies to the paper; the tested lot and form have not been established as SKU A15801.
Methods 2.2; Results 3.4; Figure 4A–C and caption
Vehicle · Methods 2.2; Results 3.4; Figure 4A–C and caption
Entrectinib · Methods 2.2; Results 3.4; Figure 4A–C and caption
Pacritinib · Methods 2.2; Results 3.4; Figure 4A–C and caption
Entrectinib + pacritinib · Methods 2.2; Results 3.4; Figure 4A–C and caption
Basal breast cancer patient-derived orthotopic xenografts
Animal study · BCM-3887 basal-subtype breast cancer PDX in female athymic nude mice [2]
Combination treatment produced the slowest tumor growth. Entrectinib monotherapy significantly suppressed growth versus vehicle, whereas pacritinib monotherapy did not.
Conditions shared by the study groups
- Route
- Oral gavage
- Frequency
- Twice daily, 5 days/week
- Treatment course
- From day 21 to study endpoint (day 35 shown).
- Vehicle
- 100% PEG
- Vehicle
- Model: BCM-3887 basal-subtype breast cancer PDX in female athymic nude mice
- Reported limits: No lot or salt designation. Vehicle composition beyond 100% PEG not specified in acquired main text.
- Entrectinib
- Model: BCM-3887 basal-subtype breast cancer PDX in female athymic nude mice
- Reported limits: No lot or salt designation. Vehicle composition beyond 100% PEG not specified in acquired main text.
- Pacritinib
- Model: BCM-3887 basal-subtype breast cancer PDX in female athymic nude mice
- Reported limits: No lot or salt designation. Vehicle composition beyond 100% PEG not specified in acquired main text.
- Entrectinib + pacritinib
- Model: BCM-3887 basal-subtype breast cancer PDX in female athymic nude mice
- Reported limits: No lot or salt designation. Vehicle composition beyond 100% PEG not specified in acquired main text.
Methods and source locations
Compound reported in the paper: Entrectinib; Compound label in the paper: Entrectinib alone or with pacritinib
Supplier attribution applies to the paper; the tested lot and form have not been established as SKU A15801.
Methods 2.2; Results 3.5; Figure 5A–D and caption
Vehicle · Methods 2.2; Results 3.5; Figure 5A, D and caption
Entrectinib · Methods 2.2; Results 3.5; Figure 5A, D and caption
Pacritinib · Methods 2.2; Results 3.5; Figure 5A, D and caption
Entrectinib + pacritinib · Methods 2.2; Results 3.5; Figure 5A, D and caption